Utilização de canabidiol como tratamento alternativo para cães com epilepsia

Utilização de canabidiol como tratamento alternativo para cães com epilepsia

• Autor
• Bruna Bistene Roque
• Co-autores
• Michele Caroline Ribeiro do Carmo Rocha , Maria Paula Rajao Costa Coelho , Eliane Gonçalves de Melo , Nathália Leijoto Pinto Lourenço
• Resumo

• 1. AMAR, Mohamed Ben. Cannabinoids in medicine: A review of their therapeutic potential. Journal of ethnopharmacology, v. 105, n. 1-2, p. 1-25, 2006.

  2. ARROL, L. et al. Aetiology and long-term outcome of juvenile epilepsy in 136 dogs. Veterinary Record, v. 170, n. 13, p. 335-335, 2012.

  3. ARZIMANOGLOU, Alexis et al. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disorders, v. 22, n. 1, p. 1-14, 2020.

  4. BAILEY, Kerry Smith et al. Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. Journal of the American Veterinary Medical Association, v. 232, n. 6, p. 867-872, 2008.

  5. BARTNER, Lisa R. et al. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Canadian Journal of Veterinary Research, v. 82, n. 3, p. 178-183, 2018.

  6. BERENDT, Mette et al. A cross?sectional study of epilepsy in Danish Labrador Retrievers: prevalence and selected risk factors. Journal of Veterinary Internal Medicine, v. 16, n. 3, p. 262-268, 2002.

  7. BERENDT, Mette et al. Premature death, risk factors, and life patterns in dogs with epilepsy. Journal of Veterinary Internal Medicine, v. 21, n. 4, p. 754-759, 2007.

  8. BERENDT, Mette; GRAM, Lennart. Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. Journal of Veterinary Internal Medicine, v. 13, n. 1, p. 14-20, 1999.

  9. BHATTI, Sofie FM et al. International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe. BMC Veterinary Research, v. 11, n. 1, p. 176, 2015.

  10. BIH, Clementino Ibeas et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, v. 12, n. 4, p. 699-730, 2015.

  11. BRUTLAG, Ahna; HOMMERDING, Holly. Toxicology of marijuana, synthetic cannabinoids, and cannabidiol in dogs and cats. Veterinary Clinics: Small Animal Practice, v. 48, n. 6, p. 1087-1102, 2018.

  12. CHANDLER, Kate. Canine epilepsy: what can we learn from human seizure disorders?. The Veterinary Journal, v. 172, n. 2, p. 207-217, 2006.

  13. CHANDLER, Kate; VOLK, Holger. Seizures: intracranial or extracranial disease?. In practice, v. 30, n. 7, p. 366-373, 2008.

  14. CONSROE, P. A. U. L.; WOLKIN, ANDREA. Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. Journal of Pharmacology and Experimental Therapeutics, v. 201, n. 1, p. 26-32, 1977.

  15. CONSROE, Paul et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. European journal of pharmacology, v. 83, n. 3-4, p. 293-298, 1982.

  16. DEVINSKY, Orrin et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology, v. 15, n. 3, p. 270-278, 2016.

  17. DEVINSKY, Orrin et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. New England Journal of Medicine, v. 378, n. 20, p. 1888-1897, 2018.

  18. DEVINSKY, Orrin et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy & Behavior, v. 86, p. 131-137, 2018.

  19. DEVINSKY, Orrin et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, v. 376, n. 21, p. 2011-2020, 2017.

  20. GRAY, Royston A.; WHALLEY, Benjamin J. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders, v. 22, p. S10-S15, 2020.

  21. GRINSPOON, Lester Grinspoon; GRINSPOON, Lester; BAKALAR, James B. Marihuana, the forbidden medicine. Yale University Press, 1997.

  22. HESKE, L. et al. A cohort study of epilepsy among 665,000 insured dogs: incidence, mortality and survival after diagnosis. The Veterinary Journal, v. 202, n. 3, p. 471-476, 2014.

  23. JONES, Nicholas A. et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure, v. 21, n. 5, p. 344-352, 2012.

  24. KALANT, Harold. Medicinal use of cannabis: history and current status. Pain Research and Management, v. 6, 2001.

  25. KLEIN, Brian D. et al. Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochemical Research, v. 42, n. 7, p. 1939-1948, 2017.

  26. MAA, Edward; FIGI, Paige. The case for medical marijuana in epilepsy. Epilepsia, v. 55, n. 6, p. 783-786, 2014.

  27. MCGRATH, Stephanie et al. A report of adverse effects associated with the administration of cannabidiol in healthy dogs. veterinary medicine, v. 1, n. 2, p. 6-8, 2018.

  28. MCGRATH, Stephanie et al. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, v. 254, n. 11, p. 1301-1308, 2019.

  29. MCPARTLAND, John M. et al. Are cannabidiol and ?9?tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British journal of pharmacology, v. 172, n. 3, p. 737-753, 2015.

  30. MONTEIRO, R. et al. Canine idiopathic epilepsy: prevalence, risk factors and outcome associated with cluster seizures and status epilepticus. Journal of Small Animal Practice, v. 53, n. 9, p. 526-530, 2012.

  31. MUÑANA, Karen R. Update: seizure management in small animal practice. Veterinary Clinics: Small Animal Practice, v. 43, n. 5, p. 1127-1147, 2013.

  32. PAMPLONA, Fabricio A.; DA SILVA, Lorenzo Rolim; COAN, Ana Carolina. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Frontiers in neurology, v. 9, p. 759, 2018.

  33. PERTWEE, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ?9?tetrahydrocannabinol, cannabidiol and ?9?tetrahydrocannabivarin. British journal of pharmacology, v. 153, n. 2, p. 199-215, 2008.

  34. PLATT, S. R. et al. Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Veterinary Record, v. 159, n. 26, p. 881-884, 2006.

  35. PODELL, M. et al. 2015 ACVIM small animal consensus statement on seizure management in dogs. Journal of Veterinary Internal Medicine, v. 30, n. 2, p. 477-490, 2016.

  36. PODELL, Michael. Antiepileptic drug therapy and monitoring. Topics in companion animal medicine, v. 28, n. 2, p. 59-66, 2013.

  37. PORCARI, Giulia S. et al. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy & Behavior, v. 80, p. 240-246, 2018.

  38. PRESS, Craig A.; KNUPP, Kelly G.; CHAPMAN, Kevin E. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy & Behavior, v. 45, p. 49-52, 2015.

  39. PROSCHOWSKY, Helle Friis; RUGBJERG, Helene; ERSBOLL, Annette Kjær. Mortality of purebred and mixed-breed dogs in Denmark. Preventive veterinary medicine, v. 58, n. 1-2, p. 63-74, 2003.

  40. SAITO, Miyoko et al. Risk factors for development of status epilepticus in dogs with idiopathic epilepsy and effects of status epilepticus on outcome and survival time: 32 cases (1990–1996). Journal of the American Veterinary Medical Association, v. 219, n. 5, p. 618-623, 2001.

  41. THIELE, Elizabeth A. et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, v. 391, n. 10125, p. 1085-1096, 2018.

  42. TZADOK, Michal et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure, v. 35, p. 41-44, 2016.

  43. VOLK, Holger A. et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. The Veterinary Journal, v. 176, n. 3, p. 310-319, 2008.

• Palavras-chave
• Epilepsia, canabidiol, cães, refratários
• Área Temática
• Clínica e Cirurgia Veterinária

Voltar Download